Exelixis Receivables 2010-2025 | EXEL

Exelixis receivables for the quarter ending June 30, 2025 were $0.292B, a 26.28% decline year-over-year.

  • Exelixis receivables for 2024 were $0.265B, a 11.81% increase from 2023.
  • Exelixis receivables for 2023 were $0.237B, a 10.53% increase from 2022.
  • Exelixis receivables for 2022 were $0.215B, a 24.01% decline from 2021.

Exelixis Receivables 2010-2025 | EXEL

  • Exelixis receivables for 2024 were $0.265B, a 11.81% increase from 2023.
  • Exelixis receivables for 2023 were $0.237B, a 10.53% increase from 2022.
  • Exelixis receivables for 2022 were $0.215B, a 24.01% decline from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$251.1B
Amgen (AMGN)$158.1B
Gilead Sciences (GILD)$142.4B
Vertex Pharmaceuticals (VRTX)$101.3B
Bristol Myers Squibb (BMY)$97.5B
GSK (GSK)$81.9B
CSL (CSLLY)$68.2B
Regeneron Pharmaceuticals (REGN)$62.5B
Alnylam Pharmaceuticals (ALNY)$59.6B
Argenex SE (ARGX)$40.4B
Insmed (INSM)$27.9B
BioNTech SE (BNTX)$26.7B
Royalty Pharma (RPRX)$21.2B
Biogen (BIIB)$20.4B
Incyte (INCY)$16.6B
Genmab (GNMSF)$16.1B
Genmab (GMAB)$15.8B
Illumina (ILMN)$15.6B
Ascendis Pharma (ASND)$11.9B
BioMarin Pharmaceutical (BMRN)$11.2B
QIAGEN (QGEN)$11.1B
Swedish Orphan Biovitrum (BIOVF)$10.9B
Moderna (MRNA)$10.6B
Exact Sciences (EXAS)$9B
Verona Pharma American Depositary Share (VRNA)$9B
Bio-Techne Corp (TECH)$8.9B
Halozyme Therapeutics (HALO)$8.4B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$8.1B
Guardant Health (GH)$7.7B